GlassScriptPhysician profile
Marc J Davis
NPI 1194763060
$4,833.01
in general payments reported to CMS, 2019-2025
29 companies · $32.24 in 2025
The $32.24 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,680 · 2020: $883 · 2021: $893 · 2022: $662 · 2023: $604 · 2024: $78.31 · 2025: $32.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,119.76 | 2019-2024 | Farxiga, Fasenra, Airsupra |
| Novo Nordisk INC | $547.46 | 2019-2024 | Rybelsus, Ozempic |
| Supernus Pharmaceuticals, INC. | $403.97 | 2019-2020 | |
| Lilly USA, LLC | $366.62 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Glaxosmithkline, LLC. | $361.91 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $268.76 | 2019-2023 | Prolia, Evenity |
| Mylan Specialty L.P. | $263.62 | 2019-2023 | Yupelri |
| Astellas Pharma US INC | $234.82 | 2019-2023 | Veozah |
| Pfizer INC. | $234.18 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.21 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $111.59 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $111.37 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.68 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.64 | 2020-2021 | |
| Abbvie INC. | $65.60 | 2021-2023 | Vraylar |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $64.72 | 2019-2020 | |
| Exact Sciences Corporation | $48.50 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $38.35 | 2020 | |
| Novartis Pharmaceuticals Corporation | $34.72 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $32.05 | 2020-2021 | |
| Dexcom, INC. | $29.23 | 2022-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $24.47 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $24.25 | 2023 | |
| Esperion Therapeutics, INC. | $23.41 | 2020 | |
| Ironwood Pharmaceuticals, INC | $18.73 | 2020 | |
| Bioventus LLC | $17.15 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.77 | 2023 | |
| Vapotherm INC | $14.92 | 2021 | |
| Millicent US INC | $12.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.